MEHLMAN CONSULTING, INC.

Lobbying for ULTRAGENYX PHARMACEUTICAL, INC. · Biopharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $60,000.00 income · posted Apr 17, 2026

Bills named in this filing 2

Lobbying activity 2

Health Issues

Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025.

Budget/Appropriations

FY 2027 Appropriations.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.